| Barchart Demo Center |
$6,68
-0,10 (-1,47%)
en date du mai 31, 2024
en date du mai 31, 2024
| Dernière | 6,68 |
|---|---|
| Variation | -0,10 (-1,47%) |
| Ouverture | 6,65 |
| Clôture précédente | 6,78 |
| Écart (actuel) |
6,51
6,79
|
| Écart 52 semaines |
2,22
6,98
|
| Volume | 1 348 400 |
| Volume Moyen | 1 462 230 |
| Secteur | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Nom | Aujourd'hui | 3-mois | 1 an |
|---|---|---|---|
| AMRX |
 -1,47% |
 +9,87% |
 +194,27% |
| DJIA |
+1,51% |
-2,09% |
+16,90% |
| S&P 500 |
+0,80% |
+1,01% |
+25,49% |
Statistiques clef
| BPA Annuel | -0,56 |
|---|---|
| Rendement dividendes | 0,00% |
| Rapport Prix/Bénéfices | 11,90 |
| Market Capitalization, $K | 2 092 660 |
| Alpha pondéré | +129,21 |
| Écart-type | -0,56 |
| Marge d'exploitation | -6,76% |
| Beta | 1,33 |
Taux de croissance
| Cette année | +10,05% | |||
| 1 An(s) | +161,96% | |||
| 3 An(s) | +22,34% | |||
| 5 An(s) | -12,68% | |||
| 10 An(s) | -75,94% |
Opinion
| Vendre | Conserver | Acheter |
Articles récents
Amneal Begins Supplying Over-the-Counter Naloxone
Business Wire - Wed May 22, 03:05PM CDT
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has begun supplying its over-the-counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg to (version intégrale)
AMRX: 6,68 (-0,10)
Amneal to Participate at Upcoming Investor Conference
Business Wire - Wed May 22, 03:05PM CDT
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 2024 Jefferies Healthcare Conference on(version intégrale)
AMRX: 6,68 (-0,10)
Amneal: Q1 Earnings Snapshot
AP - Fri May 03, 05:06AM CDT
Amneal: Q1 Earnings Snapshot(version intégrale)
AMRX: 6,68 (-0,10)
Amneal Reports First Quarter 2024 Financial Results
Business Wire - Fri May 03, 05:00AM CDT
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) announced its results today for the first quarter ended March 31, 2024.(version intégrale)
AMRX: 6,68 (-0,10)
Amneal Announces U.S. FDA Approval of Over-the-Counter
Business Wire - Wed Apr 24, 07:00AM CDT
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the availability of Over the Counter (“OTC”) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, (version intégrale)
AMRX: 6,68 (-0,10)